TP53 and adrenal cortex carcinoma: Additionally, drugs targeting p53 and WNT/b-catenin signaling, which are in early clinical development, could also be tested in ACC in combination with immunotherapy, with special consideration to tissue selectivity which is an inherent problem of these drugs.